Arthritis - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 133

Arthritis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Arthritis - Pipeline Review, H2 2012', provides an overview of the Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arthritis. 'Arthritis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Arthritis.
- A review of the Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Arthritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Arthritis Therapeutic Products under Development, Key Players in Arthritis Therapeutics, Arthritis Pipeline Overview, Arthritis Pipeline, Arthritis Pipeline Assessment

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Arthritis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Arthritis 11
Arthritis Therapeutics under Development by Companies 13
Arthritis Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Arthritis Therapeutics – Products under Development by Companies 21
Arthritis Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Arthritis Therapeutics Development 24
Baxter International Inc. 24
F. Hoffmann-La Roche Ltd. 25
Seikagaku Corporation 26
Amgen Inc. 27
Eli Lilly and Company 28
GlaxoSmithKline plc 29
Cytokine PharmaSciences, Inc. 30
Celltrion, Inc. 31
Sylentis 32
Pfizer Inc. 33
UCB Group 34
Celgene Corporation 35
Bone Medical Limited 36
Can-Fite BioPharma Ltd. 37
CSL Limited 38
Oscotec Inc. 39
AnaMar Medical AB 40
CREABILIS Therapeutics S.r.l. 41
Alder Biopharmaceuticals Inc. 42
PLx Pharma Inc. 43
Cempra Pharmaceuticals, Inc. 44
NasVax Ltd. 45
Centocor Ortho Biotech, Inc. 46
RNL BIO Co., Ltd. 47
Arthritis – Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Combination Products 49
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
CSL324 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AMG 827 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LY2439821 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Tofacitinib - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CC-10004 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cimzia - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Stelara - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ALD-518 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
GLPG0555 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CEM-102 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CF602 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Piroxicam - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Meloxicam - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
PL 5100 Diclofenac - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RG4934 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Orfadin - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
CT340 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
RO5310074 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Drug For Arthritis - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MIF Inhibitors - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CT-P05 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
DIS-BIO-OA01 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Core Targeted Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Humanized Antibody Conjugate - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Anti-aCD3 Mab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
BN005 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
BN008 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
GLPG0778 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
HZN-602 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
5-HT2 Receptor Antagonist - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Anti-MIF Antibody - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Jointstem - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
OCT-SG815 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
IL-23 Receptor Antagonists - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
SYK Inhibitors - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
ADAMTS-5 Inhibitors - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Selected Activated T Cell Death Inducers - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Selegiline + NSAIDs - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Anti-MIF Receptor Technology Platform - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Arthritis Therapeutics – Drug Profile Updates 104
Arthritis Therapeutics – Discontinued Products 119
Arthritis Therapeutics - Dormant Products 120
Arthritis – Product Development Milestones 121
Featured News & Press Releases 121
Jul 12, 2012: Celgene's Apremilast Achieves Statistical Significance For Primary Endpoint Of First Phase III Study In Patients With Psoriatic Arthritis 121
Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Enbrel 122
Jun 21, 2012: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Enbrel 123
Jun 06, 2012: UCB Presents Results From RAPID-PsA Study Of Certolizumab Pegol At EULAR Annual European Congress Of Rheumatology 125
Jun 06, 2012: Savient Pharma Presents New Analysis From Phase III Study Of KRYSTEXXA At EULAR 2012 126
Jun 05, 2012: Janssen Reports Positive Data From Phase III Study Of STELARA For Treatment Of Psoriatic Arthritis At EULAR Annual Congress 127
May 01, 2012: Pfizer Settles Celebrex Lawsuit With Brigham Young University 129
Feb 16, 2012: UCB Announces Positive Top-Line Results For Cimzia In Psoriatic Arthritis 129
Jan 26, 2012: Medipost Announces Export Of Stem Cell Arthritis Drug 130
Dec 19, 2011: Galapagos Achieves Clinical Proof-Of-Mechanism Milestone In GSK Alliance 130
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 133
Disclaimer 133

List of Tables
Number of Products Under Development for Arthritis, H2 2012 11
Products under Development for Arthritis – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 16
Comparative Analysis by Late Stage Development, H2 2012 17
Comparative Analysis by Mid Clinical Stage Development, H2 2012 18
Comparative Analysis by Early Clinical Stage Development, H2 2012 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 23
Baxter International Inc., H2 2012 24
F. Hoffmann-La Roche Ltd., H2 2012 25
Seikagaku Corporation, H2 2012 26
Amgen Inc., H2 2012 27
Eli Lilly and Company, H2 2012 28
GlaxoSmithKline plc, H2 2012 29
Cytokine PharmaSciences, Inc., H2 2012 30
Celltrion, Inc., H2 2012 31
Sylentis, H2 2012 32
Pfizer Inc., H2 2012 33
UCB Group, H2 2012 34
Celgene Corporation, H2 2012 35
Bone Medical Limited, H2 2012 36
Can-Fite BioPharma Ltd., H2 2012 37
CSL Limited, H2 2012 38
Oscotec Inc., H2 2012 39
AnaMar Medical AB, H2 2012 40
CREABILIS Therapeutics S.r.l., H2 2012 41
Alder Biopharmaceuticals Inc., H2 2012 42
PLx Pharma Inc., H2 2012 43
Cempra Pharmaceuticals, Inc., H2 2012 44
NasVax Ltd., H2 2012 45
Centocor Ortho Biotech, Inc., H2 2012 46
RNL BIO Co., Ltd., H2 2012 47
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Stage and Molecule Type, H2 2012 53
Arthritis Therapeutics – Drug Profile Updates 104
Arthritis Therapeutics – Discontinued Products 119
Arthritis Therapeutics – Dormant Products 120

List of Figures
Number of Products under Development for Arthritis, H2 2012 11
Products under Development for Arthritis – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 17
Mid Clinical Stage Products, H2 2012 18
Early Clinical Stage Products, H2 2012 19
Discovery and Pre-Clinical Stage Products, H2 2012 20
Assessment by Monotherapy Products, H2 2012 48
Assessment by Combination Products, H2 2012 49
Assessment by Route of Administration, H2 2012 50
Assessment by Stage and Route of Administration, H2 2012 51
Assessment by Molecule Type, H2 2012 52
Assessment by Stage and Molecule Type, H2 2012 53

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Premature Ejaculation – Pipeline Review, H1 2013